Corn fibre lowers LDL cholesterol but leaves blood sugar untouched

Dietary fibre has a long-standing reputation for protecting the heart, and fibres derived from corn have been attracting attention in supplement form. Yet the trial evidence on what corn-derived fibre actually does to cardiometabolic markers has been inconsistent, with individual studies pointing in different directions. That matters because fibre supplements are often presented as broad metabolic fixers, covering cholesterol, blood sugar, weight and inflammation at once. This review set out to pool the randomised trial evidence and establish which of those claims actually survive scrutiny.

The authors systematically searched the databases from their inception to May 2026 for trials in which adults were assigned at random to corn-derived dietary fibre supplementation or a comparison condition. They pooled the differences between groups across a wide panel of outcomes: total cholesterol, LDL cholesterol and the rest of the lipid profile, measures of blood sugar control, body measurements, blood pressure and C-reactive protein, a marker of inflammation. Subgroup analyses then checked whether the results differed according to how long the trials ran and how much fibre was given.

Corn-derived fibre lowered total cholesterol by 7.93 mg/dL and LDL cholesterol by 8.82 mg/dL compared with control conditions. Those lipid effects were generally consistent whatever the dose and however long the trials lasted. Everything else came back empty: blood sugar control, the other lipid measures, body measurements, blood pressure and C-reactive protein all showed no significant change. So the benefit is real but narrow, confined to the two cholesterol numbers most closely tied to cardiovascular risk.

This pooling helps resolve a previously inconsistent literature by showing where the signal actually sits: in cholesterol rather than across the metabolic board. The authors position corn-derived fibre as a possible adjunct nutritional strategy for improving the lipid profile and reducing cardiovascular risk. What the review cannot say is how supplemented corn fibre compares with simply eating more fibre-rich food, or whether the cholesterol reduction translates into fewer heart attacks and strokes. It also leaves unexplained why glycaemic and inflammatory markers failed to move at all.

If a fibre supplement appeals to you for cholesterol reasons, corn-derived fibre now has pooled trial evidence behind that specific use. The honest framing is a single-purpose tool: the same evidence finds nothing for blood sugar, weight, blood pressure or inflammation, so broader metabolic promises on a label are not supported here. A reduction of several mg/dL in LDL cholesterol is meaningful but modest, the kind of change that sits alongside overall diet, activity and any prescribed treatment rather than replacing them.